TACE Plus Atezolizumab/Bevacizumab and I-125 Seeds Brachytherapy for HCC With Branch PVTT
The present study aimed to assess the effectiveness of the combination treatment of Atezolizumab/Bevacizumab, transcatheter arterial chemoembolization (TACE) and I-125 Seeds Brachytherapy (TACE-AB-I) in patients with advanced hepatocellular carcinoma (HCC) and portal vein tumor thrombosis (PVTT). The investigators conf
| Condition(s) | Hepatocellular Carcinoma, Hepatic Portal Vein Tumor Invasion, Tumor Thrombus |
|---|---|
| Status | Recruiting |
| Phase | NA |
| Study type | Interventional |
| Summary | The present study aimed to assess the effectiveness of the combination treatment of Atezolizumab/Bevacizumab, transcatheter arterial chemoembolization (TACE) and I-125 Seeds Brachytherapy (TACE-AB-I) in patients with advanced hepatocellular carcinoma (HCC) and portal vein tumor thrombosis (PVTT). The investigators confirmed that the combination therapy yielded better survival data than the combined administration of Atezolizumab/Bevacizumab and TACE (TACE-AB) in patients with advanced HCC and Type I/II PVTT (Based on Cheng's PVTT classification). |
| Who can participate | Inclusion Criteria: * Age between18 and 75 years; * Has a diagnosis of HCC confirmed by radiology, histology, or cytology; * Type I PVTT or type II PVTT; * Child-Pugh class A; * Eastern Cooperative Group performance status (ECOG) score of 0-1; * No prior systemic therapy for HCC. * Adequate hematologic and end-organ function; * At least one measurable intrahepatic target lesion. Exclusion Criteria: * Diffuse HCC; * Cholangiocarcinoma, fibrolamellar, sarcomatoid hepatocellular carcinoma, and mixed hepatocellular/cholangiocarcinoma subtypes (confirmed by histology, or pathology) are not eligible; * Evidence of extrahepatic spread (EHS); * Any condition representing a contraindication to TACE or I-125 seeds brachytherapy as determined by the investigators; * Evidence or history of bleeding di |
| Ages | 18 Years to 75 Years |
| Sex | All |
| Lead sponsor | Third Affiliated Hospital, Sun Yat-Sen University |
| Locations | Guangzhou, Guangzhou, China |
| Start date | 2023-08-30 |
| NCT ID | NCT05984511 |
| Official listing | https://clinicaltrials.gov/study/NCT05984511 |